Return-Path: Delivered-To: andrew@sterlingcal.com Received: from reseller401.webserversystems.com by reseller401.webserversystems.com with LMTP id cPyPCKqSf2jMowgAchKAPA (envelope-from ) for ; Tue, 22 Jul 2025 08:31:22 -0500 Return-path: Envelope-to: andrew@sterlingcal.com Delivery-date: Tue, 22 Jul 2025 08:31:22 -0500 Received: from r68.info.wiley.com ([172.82.209.68]:39878) by reseller401.webserversystems.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384 (Exim 4.98.1) (envelope-from ) id 1ueD5V-00000002ONu-2jFW for andrew@sterlingcal.com; Tue, 22 Jul 2025 08:31:22 -0500 DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=info.wiley.com; s=wileypublishing; t=1753191069; bh=YEm0WFLb00UxC7i0cG1HFtnpW/AgooaSlHMqnBgylVI=; h=From:Subject:Date:To:MIME-Version:Message-ID:List-Unsubscribe: Content-Type; b=ZyBnVTsEzzJYqv5V9I4OguqClqPpdD2zIaM1sfINMjq6SVA2XJFAF7tV5qN1rRXrT 6pxmRJPUIsubXGGHPdajlGgBRJ6FzCDqUXa0kyUc4JizafoU3rZerQbTpMnvdQMBp+ ycbY8outbxg6/eOVOraM9QAq9qgn1tOHcwgNdIgFOk3jvjY7Zl+C1sV8hKTr9YMkUl +minMDY2ywmVOBPZjqNXhkctyQSEDgT6SYk8wH1vGT6MaipnlE33DJJP4jghJwrS1o f2MOn5u+5hwVPGG5lnpwn6AByfIt0zZ6gJrFbPdhQwl8sOvsg9M1NAJudy/c+PmH2B UoutHs0gfbBmA== X-MSFBL: Gkvaj6uQWUzjpztI3L+HEVVFoFnSBhY21HUs5USYTi4=|eyJnIjoicHJvZC5qb2h ud2lsZXltYXJrZXRpbmdfOWZiYWY3ZjAtNTY3ZC00NWE5LWFiMmUtNDA4YzljNTZ hNjc1IiwiciI6ImFuZHJld0BzdGVybGluZ2NhbC5jb20iLCJiIjoid2lsZXlwdWJ saXNoaW5nXzE3Mi44Mi4yMDkuNjhfcHJvZC5qb2hud2lsZXltYXJrZXRpbmdfOWZ iYWY3ZjAtNTY3ZC00NWE5LWFiMmUtNDA4YzljNTZhNjc1IiwicmNwdF9tZXRhIjp 7ICJpbiI6ICJ3aWxleXB1Ymxpc2hpbmdfbWlkX3Byb2Q4IiwgInIiOiAiYW5kcmV 3QHN0ZXJsaW5nY2FsLmNvbSIsICJtIjogIjBjM2E2MTNkLTEzNTAtNGM5MC1hNzA 0LTE1ZWE0ZmM1YjdjMSIsICJkIjogIjY1NjU0NjEiLCAiaSI6ICIxQjZFMzRCODU yODJBMEFDMEE0OTBENDRAQWRvYmVPcmciIH19 Received: from [10.1.1.136] ([10.1.1.136:35767] helo=r66.info.wiley.com) by or2-prod1-mta-i-0ec1de4ccb2c86551 (envelope-from ) (ecelerity 4.4.1.20033 r(msys-ecelerity:tags/4.4.1.0^0)) with ESMTP id 13/6B-50900-D929F786; Tue, 22 Jul 2025 13:31:09 +0000 From: "Wiley" Subject: =?windows-1252?Q?How_Sequence_Variants_Impact_Drug_Efficacy_=96_?= =?windows-1252?Q?Register_Today?= Date: Tue, 22 Jul 2025 09:31:09 -0400 To: Reply-To: "Wiley" MIME-Version: 1.0 X-mailer: nlserver, Build 8.6.4 Message-ID: List-Unsubscribe: Content-Type: text/html; charset="windows-1252" Content-Transfer-Encoding: quoted-printable X-Spam-Status: No, score=-4.2 X-Spam-Score: -41 X-Spam-Bar: ---- X-Spam-Flag: NO

If you are unable to view this message correctly, click her= e

 
3D"Wiley"
 
 

You=92re invited
Sequence vari= ants pose critical risks to protein therapeutic efficacy, stability, and sa= fety. In this exclusive webinar, you=92ll gain actionable strategies to det= ect and mitigate these hidden threats=97directly from industry pioneers.
Join us for an in-depth session where you=92ll:
 
•
<= span style=3D"font-size: 14px;">Impact of Variants: See ho= w protein sequence variants can affect drug efficacy, stability, and immune= response.
•
<= span style=3D"font-size: 14px;">Detection Techniques: Expl= ore icIEF-UV/MS on the Intabio ZT and EAD-enabled LC/MS on the ZenoTOF 7600= for variant detection.
•
<= span style=3D"font-size: 14px;">Real-World Application: Le= arn how one team uncovered a novel sequence variant and created a mitigatio= n strategy.
This is your = opportunity to stay ahead in the evolving world of protein therapeutics. Wh= ether you're working in analytical development, cell line engineering, qual= ity and regulatory, or program management, this webinar offers valuable ins= ights to support your success.

Register now to reserve your place and elevate your expertise!

All attendees will receive an attendance certificate.
 
 

Speaker information
Kristen Nields
Principal Scientist
Johnson & Johnson Innovative Medicine
Kristen Nields is the Principal Scientist in the Cell and Developab= ility Group at Johnson & Johnson Innovative Medicine with 20+ years of expe= rience in the biopharma industry. She specializes in bridging mass spectrom= etry and product quality functions to enhance communication. Kristen is rec= ognized for developing innovative analytical methods within the Johnson & J= ohnson organization to close product knowledge gaps.
Riley Schaefer
Co-Op Scientist II
Johnson & Johnson Innovative Medicine
Riley Schaefer is a recent honors graduate from St. Joseph=92s Univ= ersity with a B.S. in Biochemistry. He currently works as the Analytical Ce= ll Engineering & Development Co-Op at Johnson & Johnson Innovative Medicine= . His focus is on developing analytical methods to assess the biophysical p= roduct quality of monoclonal and multi-specific antibodies for the purpose = of engineering an array of manufacturing cell lines.
This virtua= l seminar has been made possible through sponsorship from Sciex.
3D"Wiley"

3D"Facebook"  = ;     3D"X" &nb= sp;         =   3D"Instagram"

   = ;  

This message was sent to andrew@sterlingcal= .com by John Wiley & S= ons, Inc.

Americas: 111 River Street | Hoboken, NJ 07030-5774 USA | +1 877 = 762 2974
EMEA: New Era House, 8 Oldlands Way, Bognor Regis, West Sussex PO= 22 9NQ, UK | +44 1243 843222
Australia: Level 4 | 600 Bourke St | Melbourne | Victoria 3000 | = Australia | +61 7 3859 9611
Asia: No. 18 Capitol Singapore, 13 Stamford Road, #02-11 | Singap= ore 178905 | +65 6643 8000
Update Subscription Preferences | Unsubscri= be
= We respect your privacy. See our privacy policy
About Wiley | Contact Customer Service

=A9 John Wiley & Sons, Inc.= All rights reserved.
3D''